Oxaliplatin-based chemotherapy in the management of colorectal cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 8, 2008, Pages 1223-1236

  Capdevila, Jaume ^a   Elez, Elena ^a   Peralta, Sergio ^a   Macarulla, Teresa ^a   Ramos, Francisco Javier ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Adjuvant treatment; Advanced disease; Bevacizumab; Cetuximab; Colorectal cancer; Mechanism of action; Neurotoxicity; Oxaliplatin

Indexed keywords

AMIFOSTINE; BEVACIZUMAB; CAPECITABINE; CARBAMAZEPINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; GEMCITABINE; GINKGO BILOBA EXTRACT; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE; THIOCTIC ACID; XALIPRODEN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT THERAPY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DYSESTHESIA; DYSPHAGIA; DYSPNEA; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LIVER SURGERY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PROGNOSIS; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; STRUCTURE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 54549105244     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.8.1223     Document Type: Review

References (88)

1. Colorectal Cancer Collaborative G. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321(7260), 531-535 (2000).
2. Saltz, LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343(13), 905-914 (2000).
3. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000).
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
5. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013-2019 (2008).
6. Rosenberg B, VanCamp, L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 26(222), 385-386 (1969).
7. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25(Suppl. 5), 4-12 (1998).
8. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in tile cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol. 24(12), 1855-1865 (1996).
9. Woynarowski JM, Chapman WG, Napier C, Herzig MCS, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 54(5), 770-777 (1998).
10. Boyer J, McLean EG, Aroori S et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res. 10(6), 2158-2167 (2004).
11. Synold TW Takimoto CH, Doroshow JH et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute organ dysfunction working group study. Clin. Cancer Res. 13(12), 3660-3666 (2007).
12. Raymond E, Buquet-Fagot C, Djelloul S et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 8(9), 876-885 (1997).
13. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res. 5(5), 1189-1196 (1999).
14. Mathé G, Kidani Y, Triana K et al. A Phase I trial of trans-1-diaminocyclohexane oxalato-platinum (L-OHP). Biomed Pharmacother. 40(10), 372-376 (1986).
15. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25(4), 299-303 (1990).
16. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc. Am. Soc. Clin. Oncol. 25(18S), (2007) (Abstract 4007).
17. Eloxatin®, product characteristics. Sanofi, Gentilly Cedex, France.
18. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7(1), 95-98 (1996).
19. Levi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectal cancer. A Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer 29(9), 1280-1284 (1993).
20. Diaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. Oncol. 9(1), 105-108 (1998).
21. Becouarn Y, Ychou M, Ducreux M et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol. 16(8), 2739-2744 (1998).
22. De Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 33(2), 214-219 (1997).
23. Andre T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 9(11), 1251-1253 (1998).
24. Levi FA, Zidani R, Vannetzel J-M et al. Chronomodulated versus fixed-infusion - rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multiinstitutional trial. J Natl Cancer Inst. 86(21), 1608-1617 (1994).
25. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III Trial. J. Clin. Oncol. 21(11), 2059-2069 (2003).
26. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22(1), 23-30 (2004).
27. Tournigand C, Andre T, Achille E et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).
28. Grothey A, Jordan K, Kellner O et al. Randomized Phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 1022).
29. Cassidy J, Tabernero J, Twelves C et al. ULOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 22(11), 2084-2091 (2004).
30. Porschen R. Arkenau. H-T, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J. Clin. Oncol. 25(27), 4217-4223 (2007).
31. Diaz-Rubio E, Tabemero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin compared with commuous-infusion fluorouracil plus oxalipladn as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the treatment of digestive tumors trial. J. Clin. Oncol. 25(27), 4224-4230 (2007).
32. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/ folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26(12), 2006-2012 (2008).
33. Rothenberg M, Navarro M, Butts CA et al. Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase II trial results. Eur. J. Cancer 5(4) (2007) (Abstract A3012).
34. Arkenau HT, Graeven U, Kubicka. S et al. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin. Colorectal Cancer 7(1), 60-64 (2008).
35. Figer A, Perez-Staub N, Carola E et al. FOLFOX in panent, aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110(12), 2666-2671 (2007).
36. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol. 24(25), 4085-4091 (2006).
37. Feliu J, Salud A, Escudero P et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br. J. Cancer 94(7), 969-975 (2006).
38. Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 104(2), 282-289 (2005).
39. Twelves CJ, Butts CA, Cassidy J et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large Phase II study. Clin. Colorectal Cancer 5 (2), 101-107 (2005).
40. Abad A. Massutí B, Antón A et al. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a Phase II study. Acta Oncol. 22, 1-7 (2007).
41. Masi G, Allegrini G, Cupini S et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a Phase II study with a simplified biweekly schedule. Ann. Oncol. 15(12), 1766-1772 (2004).
42. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25(13), 1670-1676 (2007).
43. Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised Phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer 94(6), 798-805 (2006).
44. Tabernero J, Van Cutsem. E, Diaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25(33), 5225-5232 (2007).
45. Borner M, Koeberle D, Von Moos R et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized Phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann. Oncol. 19(7), 1288-1292 (2008).
46. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectuin (MCRC): CALGB 80203 preliminary results. Proc. Am. Soc. Clin. Oncol. 24(18S), 3509 (2006).
47. Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/ FA/oxatiplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized Phase II study. Proc. Am. Soc. Clin. Oncol. 25(18S), 4035 (2007).
48. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated - metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
49. Hochster HS, Welles L, Hart L et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Proc. Am. Soc. Clin. Oncol. 23(16S), 3515 (2005).
50. Hochster HS, Hart L, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J. Clin. Oncol. 24(18S), 3510 (2006).
51. Bismuth H, Adam R, Lévi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224(4), 509-520 (1996).
52. Alberts SR, Donohue JH, Mahoney MR et al. Liver resection after 5-fluorouracil, leucovorin and oxatiplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: a North Central Cancer Treatment Group (NCCTG) Phase 11 study. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 1053).
53. Julie C, Lutz MP, Aust D et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup Phase III study 40983. Presented at: 2007 Gastrointestinal Cancers Symposium. FI, USA, 19-21 January (2007) (Abstrata 241).
54. Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC Intergroup randomized Phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Proc. Am. Soc. Clin. Oncol. 25(18S), (2007) (Abstract LBA5).
55. Gruenberger B, Scheithauer W, Tamandl D et al. Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 24(18S), (2006) (Abstract 3546).
56. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 23(34), 8664-8670 (2005).
57. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004).
58. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results hom NSABP C-07. J. Clin. Oncol. 25(16), 2198-2204 (2007).
59. Wolmark N, Wieand S, Kuebler PJ, Colangelo L, O'Connell MJ, Yothers G. A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: survival results of NSABP protocol C-07. Proc. Am. Soc. Clin. Oncol. (2008) (Abstract LBA4005).
60. Schmoll H-J, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol. 25(1), 102-109 (2007).
61. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Wolmark N. Initial safety report of NSABP C-08, a randomized Phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. Proc. Am. Soc. Clin. Oncol. 26(Suppl. 15) (2008) (Abstract 4006).
62. Cividalli A, Ceciarelli F, Livdi E et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int. J. Radiat. Oncol. Biol. Phys. 52(4), 1092-1098 (2002).
63. Freyer G, Bossard N, Romestaing P et al. Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 Phase I trial. J. Clin. Oncol. 19(9), 2433-2438 (2001).
64. Gerard J-P, Chapet O, Nemoz C et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 Phase II trial. J. Clin. Oncol. 21(6), 1119-1124 (2003).
65. Gambacorta MA, Valentini V, Coco C et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies. Int. J. Radiat. Oncol. Biol. Phys. 60(1), 139-148 (2004).
66. Eloxatin®, package insert. Sanofi-Synthelabo, Inc., NY, USA.
67. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol. 20(7), 1767-1774 (2002).
68. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 85(5), 2293-2297 (2001).
69. Luo FR, Wyrick SD, Chaney SG. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother. Pharmacol. 44(1), 29-38 (1999).
70. Maindrault-Goebel F, Tournigand C, Andre T et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann. Oncol. 15(8), 1210-1214 (2004).
71. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J. Clin. Oncol. 24(3), 394-400 (2006).
72. Maindrault-Goebel F, Lledo G, Chibaudel B et al. OPTIMOX2, a large randomized Phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc. Am. Soc. Clin. Oncol. 25(18S) (2007) (Abstract 4013).
73. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin. Oncol. 20(16), 3478-3483 (2002).
74. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmarol. 25(2), 228-234 (1984).
75. Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch. Med. Wochenschr. 127(3), 78-82 (2002).
76. Von Delius S, Eckel F, Wagenpfeil S et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter Phase II study. Invest. New Drugs 25 (2), 173-180 (2007).
77. Mitchell PL, Goldstein D, Michael M et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin. Colorectal Cancer 6(2), 146-151 (2006).
78. Gamelin L, Boisdron-Celle M, Delva R et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 10(12), 4055-4061 (2004).
79. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J. Glin. Oncol. 25(25), (2007) (Abstract 4028).
80. Hochster HS, Grothey A, Shpilsky A, Childs BH. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Presented at: 2008 Gastrointestinal Cancers Symposium. FL, USA, 25-27 January, 2008.
81. Grothey A, Hart L, Rowland KM et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the Phase III CONcePT trial. Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 40 10).
82. Nikcevich DA, Grothey A, Sloan JA et al. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the Phase III placebo-controlled, double-blind NCCTG trial N04C7. Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 4009).
83. Gamelin L, Boisdron-Celle M, Morel A et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J. Clin. Oncol. 26(7), 1188-1189 (2008).
84. Cassidy J, Bjarnason GA, Hickish T et al. Randomized double blind (DB) placebo (Plcb) controlled Phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxatiplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 24(18S), (2006) (Abstract 3507).
85. Agafitei RD, Schneider S, Iqbal S, Yang D, Groshen S, Lenz HJ. Effect of celecoxib on neurotoxicity in patients with metastatic colorectat cancer treated with 5-FU/oxaliplatin (CIFOX). Prot. Am. Soc. Clin. Oncol. 22(14S), (2004) (Abstract 3600).
86. Marshall J, Zakari A, Hwang JJ, Papadopoulos V, Rosenberg A, Silver C. Ginkgo Biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)induced neuropathy. Proc. Am. Soc. Clin. Oncol. 22(14S), (2004) (Abstract 3670).
87. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann. Oncol. 12(3), 421-422 (2001).
88. Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with α-lipoic acid. J. Clin. Oncol. 20(15), 3359-3361 (2002).